Tel Aviv – – September 30, 2026 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) has acquired U.S. commercialization rights to two FDA-approved gastrointestinal drugs, Rebyota and Clenpiq, which generated a combined $37.5 million in 2025 net sales under Ferring Pharmaceuticals.
RedHill funds $12 million Ferring deal entirely with Talicia divestment proceeds
The $12 million upfront payment for Rebyota and Clenpiq was fully covered by the $18 million upfront cash RedHill received for divesting its 70% stake in Talicia to Apotex in August 2026, a transaction that also carries up to $35 million in potential net sales milestone payments. CEO Dror Ben-Asher said the deals "unlock significant value and fuel our capacity for growth."
Rebyota adds fecal microbiota transplant therapy generating $16.9 million in 2025
Rebyota, FDA-approved in 2022 as the first single-dose fecal microbiota transplant to prevent recurrent Clostridioides difficile infection, posted $16.9 million in U.S. net sales last year and reported a success rate exceeding 70% in preventing infection recurrence. The drug carries Breakthrough Therapy and Orphan Drug designations, with patent protections extending to 2036, and recently gained approval in Canada. C. diff infections cause an estimated 3.6 million cases globally each year and 30,000 U.S. deaths annually.
Clenpiq bowel-prep brand contributed $20.6 million in sales with minimal prior promotion
Clenpiq, a ready-to-drink low-volume bowel preparation used ahead of the more than 15 million annual U.S. colonoscopies, delivered $20.6 million in 2025 net sales under Ferring despite limited marketing investment. The product holds unrestricted commercial coverage for 108 million lives and unrestricted Medicare Part D access for 23 million lives.
Pipeline advances include rare pediatric disease designation for neuroblastoma candidate opaganib
The FDA granted opaganib rare pediatric disease designation for neuroblastoma, opening potential eligibility for a Priority Review Voucher. New preclinical data presented at the 2026 AACR Annual Meeting showed opaganib may enhance chemotherapy efficacy in high-risk neuroblastoma and potentiate anti-tumor immunity in triple-negative breast cancer. RedHill continues Ebola virus disease (Bundibugyo strain) development discussions with the African Medicines Agency, Uganda's Ministry of Health, Mbarara University of Science and Technology, and the DRC Scientific Advisory Committee, while a Bayer-supported Phase 2 study of opaganib with darolutamide in prostate cancer continues recruiting patients.